指南与共识心力衰竭与心肌病

基于30天风险标准化死亡率的医院绩效与心衰住院后长期生存的关联

Association of Hospital Performance Based on 30-Day Risk-Standardized Mortality Rate With Long-term Survival After Heart Failure Hospitalization: An Analysis of the Get With The Guidelines-Heart Failure Registry.
指南 / 共识 · JAMA Cardiol · 2018-01-01

该研究纳入106 304例心衰住院患者,来自317家参与Get With The Guidelines-HF注册的中心,计算医院30天风险标准化死亡率(RSMR),并评估其与长期生存的关联。结果显示,30天RSMR较低的医院,患者1年、3年和5年生存率更高;30天RSMR可作为心衰绩效指标以改善长期结局。

要点

  • 医院30天RSMR较低与心衰患者1年、3年、5年生存率较高相关。
  • 30天RSMR较高医院的患者5年死亡风险相对增加14%(95%CI 10-18)。
  • 30天RSMR可能作为心衰绩效指标,激励质量改进并改善长期结局。

核心结论

  • 较低的医院30天RSMR与心衰患者更好的1年、3年和5年生存相关。
  • 30天生存差异在30天后继续累积并长期持续,提示30天RSMR可作为心衰绩效指标。

研究设计与样本

  • 医院30天RSMR采用分层逻辑回归模型计算,30天死亡为二分类结局,患者基线特征为协变量,医院为随机效应。
  • 按30天RSMR将医院分为四分位组(Q1至Q4),采用校正Cox模型评估与长期(1年、3年、5年)死亡率的关联。

主要发现

  • 30天RSMR范围从8.6%(Q1)至10.7%(Q4)。
  • 低30天RSMR组医院更常具备先进心衰治疗、心脏外科手术和经皮冠状动脉介入治疗能力。
  • 在30天存活者的主要界标分析中,30天RSMR与长期死亡率呈分级负相关(Q1 vs Q4:5年死亡率73.7% vs 76.8%)。
  • 校正分析中,高30天RSMR组医院患者5年死亡相对风险较低30天RSMR组高14%(95%CI 10-18)。
  • 从入院开始的生存分析中,Q4 vs Q1医院患者5年死亡相对风险高22%(95%CI 18-26)。

临床怎么用

  • 可将医院30天RSMR作为心衰绩效指标,用于激励质量改进。
  • 关注30天RSMR较高医院的长期结局,可能需加强心衰治疗能力和资源配备。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Among patients hospitalized with heart failure (HF), the long-term clinical implications of hospitalization at hospitals based on 30-day risk-standardized mortality rates (RSMRs) is not known. OBJECTIVE: To evaluate the association of hospital-specific 30-day RSMR with long-term survival among patients hospitalized with HF in the American Heart Association Get With The Guidelines-HF registry. DESIGN, SETTING, AND PARTICIPANTS: The longitudinal observational study included 106 304 patients with HF who were admitted to 317 centers participating in the Get With The Guidelines-HF registry from January 1, 2005, to December 31, 2013, and had Medicare-linked follow-up data. Hospital-specific 30-day RSMR was calculated using a hierarchical logistic regression model. In the model, 30-day mortality rate was a binary outcome, patient baseline characteristics were included as covariates, and the hospitals were treated as random effects. The association of 30-day RSMR-based hospital groups (low to high 30-day RSMR: quartile 1 [Q1] to Q4) with long-term (1-year, 3-year, and 5-year) mortality was assessed using adjusted Cox models. Data analysis took place from June 29, 2017, to February 19, 2018. EXPOSURES: Thirty-day RSMR for participating hospitals. MAIN OUTCOMES AND MEASURES: One-year, 3-year, and 5-year mortality rates. RESULTS: Of the 106 304 patients included in the analysis, 57 552 (54.1%) were women and 84 595 (79.6%) were white, and the median (interquartile range) age was 81 (74-87) years. The 30-day RSMR ranged from 8.6% (Q1) to 10.7% (Q4). Hospitals in the low 30-day RSMR group had greater availability of advanced HF therapies, cardiac surgery, and percutaneous coronary interventions. In the primary landmarked analyses among 30-day survivors, there was a graded inverse association between 30-day RSMR and long-term mortality (Q1 vs Q4: 5-year mortality, 73.7% vs 76.8%). In adjusted analysis, patients admitted to hospitals in the high 30-day RSMR group had 14% (95% CI, 10-18) higher relative hazards of 5-year mortality compared with those admitted to hospitals in the low 30-day RSMR group. Similar findings were observed in analyses of survival from admission, with 22% (95% CI, 18-26) higher relative hazards of 5-year mortality for patients admitted to Q4 vs Q1 hospitals. CONCLUSIONS AND RELEVANCE: Lower hospital-level 30-day RSMR is associated with greater 1-year, 3-year, and 5-year survival for patients with HF. These differences in 30-day survival continued to accrue beyond 30 days and persisted long term, suggesting that 30-day RSMR may be a useful HF performance metric to incentivize quality care and improve long-term outcomes.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Pandey A, Patel KV, Liang L, et al. Association of Hospital Performance Based on 30-Day Risk-Standardized Mortality Rate With Long-term Survival After Heart Failure Hospitalization: An Analysis of the Get With The Guidelines-Heart Failure Registry. JAMA Cardiol. 2018. PMID: 29532056. doi:10.1001/jamacardio.2018.0579

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。